| |
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now. 
|
|
Today’s Big NewsAug 9, 2024 |
|
Cell therapy developers face many challenges as they transition from benchtop to bedside. Here we examine when and how to consider transitioning from research-use-only to animal-free (AF) and GMP critical reagents. Download now. 
|
|
| By Kevin Dunleavy With Gilead on the verge of an FDA decision for its liver disease drug seladelpar, the company has paid Johnson & Johnson $320 million to exit an 18-year-old licensing agreement on the compound. The buyout removes Gilead’s obligation to pay an 8% royalty on sales of seladelpar. |
|
|
|
By Heather Landi Zimmer Biomet plans to acquire AI surgical guidance company OrthoGrid Systems to expand its market share in hip replacement procedures. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Andrea Park To brew up the latest iteration of its ongoing initiative to provide deeper education around chronic skin conditions, AbbVie sought help from a onetime teenage witch. |
|
Dive into the cutting-edge world of recombinant antibody engineering, from optimizing your antibody plasmid to antibody maturation and humanization. Explore innovative techniques and strategies that enhance antibody efficacy, paving the way for breakthroughs in therapeutic development. Download now. 
|
|
By Angus Liu Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged. |
By Nick Paul Taylor Merck & Co. is paying $700 million upfront to challenge Amgen in a blood cancer market. The deal will give Merck global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific, positioning the Big Pharma as a rival to Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune disease. |
By Zoey Becker The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study. |
By Kevin Dunleavy As Novavax presented its quarterly earnings, finance chief Jim Kelly said the company was “actively exploring” the sale of its manufacturing facility in the Czech Republic. Novavax purchased the site in May of 2020 for $167 million with the intent of it producing more than 1 billion doses annually there. It was part of a dizzying scale up when the company—fueled by government funding—was awash with outsized expectations. |
By Darren Incorvaia,Zoey Becker,Gabrielle Masson Former Biogen Chief Medical Officer Maha Radhakrishnan, M.D., is now an executive partner at healthcare investment firm Sofinnova Investments. |
By Ben Adams Crinetics is seeking to change the way acromegaly is treated. Ahead of its hopes for a 2025 U.S. drug launch, the biotech is looking to spread awareness about how to treat the condition. |
By Nick Paul Taylor AN2 Therapeutics is rethinking its business in response to lackluster midphase data, vowing to lay off half its employees and stop a phase 3 study as part of a pivot to early-stage projects. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. |
|
|---|
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
